{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:19:49Z","timestamp":1791404389507,"version":"4.3.3"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007688","name":"American University of Beirut","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.semcancer.2019.05.018","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T11:29:44Z","timestamp":1559129384000},"page":"83-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Novel therapeutic strategies for spinal osteosarcomas"],"prefix":"10.1016","volume":"64","author":[{"given":"M. Akhtar","family":"Anwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirine","family":"El-Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed H.","family":"Elnaggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen O.","family":"Elkholy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Mottawea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Johar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuqa S.","family":"Al Shehabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Kobeissy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charbel","family":"Moussalem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Massaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Omeis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Darwiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H.","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semcancer.2019.05.018_bib0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"12","key":"10.1016\/j.semcancer.2019.05.018_bib0010","first-page":"e1288","article-title":"Effect on longevity of one-third reduction in premature mortality from non-communicable diseases by 2030: a global analysis of the Sustainable Development Goal health target, the Lancet","volume":"6","author":"Cao","year":"2018","journal-title":"Global Health"},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0015","first-page":"7","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.semcancer.2019.05.018_bib0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11864-015-0345-5","article-title":"Immunotherapeutic approaches to sarcoma","volume":"16","author":"Burgess","year":"2015","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2017.05.006","article-title":"Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies","volume":"58","author":"Park","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"10.1016\/j.semcancer.2019.05.018_bib0030","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/14712598.2016.1188075","article-title":"The future of immunotherapy for sarcoma","volume":"16","author":"Tsukahara","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"issue":"5","key":"10.1016\/j.semcancer.2019.05.018_bib0035","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40272-018-0297-x","article-title":"Pediatric Cancer immunotherapy: opportunities and challenges","volume":"20","author":"Wedekind","year":"2018","journal-title":"Paediatr. Drugs"},{"issue":"2","key":"10.1016\/j.semcancer.2019.05.018_bib0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40744-016-0046-y","article-title":"Review of osteosarcoma and current management","volume":"3","author":"Durfee","year":"2016","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0045","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4137\/CMO.S10099","article-title":"Spinal osteosarcoma","volume":"7","author":"Katonis","year":"2013","journal-title":"Clin. Med. Insights Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.nec.2007.10.001","article-title":"Sarcoma and the Spinal Column","volume":"19","author":"Wang","year":"2008","journal-title":"Neurosurg. Clin. N. Am."},{"issue":"54","key":"10.1016\/j.semcancer.2019.05.018_bib0055","first-page":"104","article-title":"The WHO classification of bone tumors, Recent results in cancer research. Fortschritte der Krebsforschung","author":"Sissons","year":"1976","journal-title":"Progres dans les recherches sur le cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2019.05.018_bib0060","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/jcp.33.4.415-b","article-title":"Bone tumors: diagnosis, treatment and prognosis","volume":"33","author":"Gowing","year":"1980","journal-title":"J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.semcancer.2019.05.018_bib0065","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00586-006-0188-7","article-title":"Primary bone tumours of the spine: a 42-year survey from the Leeds Regional Bone Tumour Registry","volume":"16","author":"Kelley","year":"2007","journal-title":"Eur. Spine J."},{"issue":"August","key":"10.1016\/j.semcancer.2019.05.018_bib0070","first-page":"1","article-title":"Primary bone tumors","volume":"41","author":"Ravindra","year":"2016","journal-title":"Pediatric Column"},{"issue":"8","key":"10.1016\/j.semcancer.2019.05.018_bib0075","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jocn.2011.09.035","article-title":"Cervical spinal osteosarcoma in an adolescent","volume":"19","author":"Chan","year":"2012","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0080","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11420-006-9007-2","article-title":"Paget\u2019s disease of the spine and secondary osteosarcoma","author":"Sofka","year":"2006","journal-title":"HSS J."},{"issue":"4","key":"10.1016\/j.semcancer.2019.05.018_bib0085","doi-asserted-by":"crossref","first-page":"747","DOI":"10.7326\/0003-4819-71-4-747","article-title":"Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?","volume":"71","author":"Li","year":"1969","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/jnci\/djk002","article-title":"Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma","volume":"99","author":"Kleinerman","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0095","series-title":"GeneReviews((R))","article-title":"Bloom syndrome","author":"Flanagan","year":"1993"},{"issue":"4","key":"10.1016\/j.semcancer.2019.05.018_bib0100","first-page":"239","article-title":"Excess of rare cancers in Werner syndrome (adult progeria)","volume":"5","author":"Goto","year":"1996","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"12","key":"10.1016\/j.semcancer.2019.05.018_bib0105","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1349-7006.2000.tb00924.x","article-title":"Atypical osteosarcomas in Werner Syndrome (adult progeria)","volume":"91","author":"Ishikawa","year":"2000","journal-title":"Jpn. J. Cancer Res."},{"issue":"3","key":"10.1016\/j.semcancer.2019.05.018_bib0110","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1302\/0301-620X.66B3.6586725","article-title":"Parosteal osteosarcoma","volume":"66","author":"Campanacci","year":"1984","journal-title":"J. Bone Jt. Surg."},{"issue":"5","key":"10.1016\/j.semcancer.2019.05.018_bib0115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1053\/hp.2000.6702","article-title":"Repeated dedifferentiation of low-grade intraosseous osteosarcoma","volume":"31","author":"Ogose","year":"2000","journal-title":"Hum. Pathol."},{"issue":"4","key":"10.1016\/j.semcancer.2019.05.018_bib0120","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1309\/UC6KQHLD9LV2KENN","article-title":"Osteosarcoma: anatomic and histologic variants","volume":"125","author":"Klein","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"issue":"10","key":"10.1016\/j.semcancer.2019.05.018_bib0125","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2136::AID-CNCR14>3.0.CO;2-#","article-title":"Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome","volume":"78","author":"Sheth","year":"1996","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1302\/0301-620X.84B1.0840088","article-title":"Osteosarcoma of the spine","volume":"84","author":"Bacci","year":"2002","journal-title":"J. Bone Jt. Surg."},{"issue":"4","key":"10.1016\/j.semcancer.2019.05.018_bib0135","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/cncr.10258","article-title":"Osteosarcoma of the spine: experience of the cooperative osteosarcoma study group","volume":"94","author":"Ozaki","year":"2002","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2019.05.018_bib0140","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/cncr.22574","article-title":"Telangiectatic osteosarcoma: the St. Jude children\u2019s research hospital\u2019s experience","volume":"109","author":"Weiss","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2019.05.018_bib0145","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00776-007-1114-5","article-title":"Invasive features of spinal osteosarcoma obtained from whole-mount sections of total en bloc spondylectomy","volume":"12","author":"Murakami","year":"2007","journal-title":"J. Orthop. Sci."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0150","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/BLO.0b013e318059b8c9","article-title":"Osteosarcoma, chondrosarcoma, and Ewing\u2019s sarcoma: national Cancer data base report","volume":"459","author":"Damron","year":"2007","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3171\/jns.1993.78.1.0036","article-title":"The natural history and management of symptomatic and asymptomatic vertebral hemangiomas","volume":"78","author":"Fox","year":"1993","journal-title":"J. Neurosurg."},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4184\/asj.2012.6.1.71","article-title":"Metastatic spinal tumor","volume":"6","author":"Lee","year":"2012","journal-title":"Asian Spine J."},{"issue":"3","key":"10.1016\/j.semcancer.2019.05.018_bib0165","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1148\/radiol.2303030226","article-title":"Primary vertebral osteosarcoma: imaging findings","volume":"230","author":"Ilaslan","year":"2004","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.semcancer.2019.05.018_bib0170","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1148\/radiology.175.3.2160676","article-title":"Fluid-fluid level: a nonspecific finding in tumors of bone and soft tissue","volume":"175","author":"Tsai","year":"1990","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.semcancer.2019.05.018_bib0175","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1148\/radiol.2292021130","article-title":"Telangiectatic osteosarcoma: radiologic-pathologic comparison","volume":"229","author":"Murphey","year":"2003","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.semcancer.2019.05.018_bib0180","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/01.RLU.0000057556.54046.7A","article-title":"Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG","volume":"28","author":"Nakamoto","year":"2003","journal-title":"Clin. Nucl. Med."},{"issue":"3","key":"10.1016\/j.semcancer.2019.05.018_bib0185","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00586-006-0188-7","article-title":"Primary bone tumours of the spine: a 42-year survey from the Leeds Regional Bone Tumour Registry","volume":"16","author":"Kelley","year":"2007","journal-title":"Eur. Spine J."},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00007632-199001000-00001","article-title":"Spinal metastases: the obvious, the occult, and the impostors","volume":"15","author":"Wong","year":"1990","journal-title":"Spine"},{"issue":"9","key":"10.1016\/j.semcancer.2019.05.018_bib0195","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007632-199705010-00020","article-title":"Primary bone tumors of the spine. Terminology and surgical staging","volume":"22","author":"Boriani","year":"1997","journal-title":"Spine"},{"issue":"15","key":"10.1016\/j.semcancer.2019.05.018_bib0200","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1097\/00007632-199708010-00018","article-title":"A system for surgical staging and management of spine tumors. A clinical outcome study of giant cell tumors of the spine","volume":"22","author":"Hart","year":"1997","journal-title":"Spine"},{"issue":"153","key":"10.1016\/j.semcancer.2019.05.018_bib0205","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00003086-198011000-00013","article-title":"A system for the surgical staging of musculoskeletal sarcoma","author":"Enneking","year":"1980","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"204","key":"10.1016\/j.semcancer.2019.05.018_bib0210","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00003086-198603000-00003","article-title":"A system of staging musculoskeletal neoplasms","author":"Enneking","year":"1986","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"7","key":"10.1016\/j.semcancer.2019.05.018_bib0215","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/00007632-200004010-00008","article-title":"Chondrosarcoma of the mobile spine: report on 22 cases","volume":"25","author":"Boriani","year":"2000","journal-title":"Spine"},{"key":"10.1016\/j.semcancer.2019.05.018_bib0220","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3389\/fphar.2018.01300","article-title":"Evolution of Cancer Pharmacological treatments at the turn of the third millennium","volume":"9","author":"Falzone","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0225","doi-asserted-by":"crossref","first-page":"250","DOI":"10.20517\/2394-4722.2017.41","article-title":"Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead","volume":"3","author":"Oiseth","year":"2017","journal-title":"J. Cancer Metastasis Treat."},{"issue":"18","key":"10.1016\/j.semcancer.2019.05.018_bib0230","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1158\/1078-0432.CCR-18-2756","article-title":"AACR cancer progress report 2018: harnessing research discoveries for patient benefit","volume":"24","author":"Sengupta","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.semcancer.2019.05.018_bib0235","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/17512433.2018.1504677","article-title":"Overview of precision oncology trials: challenges and opportunities","volume":"11","author":"Fountzilas","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.semcancer.2019.05.018_bib0240","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/JCO.1989.7.4.477","article-title":"A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma","volume":"7","author":"Dutcher","year":"1989","journal-title":"J. Clin. Oncol."},{"issue":"5022","key":"10.1016\/j.semcancer.2019.05.018_bib0245","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/bmj.1.5022.779","article-title":"Cancer; a biological approach. I. The processes of control","volume":"1","author":"Burnet","year":"1957","journal-title":"Br. Med. J."},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.semcancer.2019.05.018_bib0255","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2018.02.004","article-title":"Targeting the microenvironment in solid tumors","volume":"65","author":"Belli","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0260","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/978-3-319-67577-0_13","article-title":"Immunotherapeutic targeting of tumor-associated blood vessels","volume":"1036","author":"Fabian","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0265","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.3389\/fimmu.2018.02517","article-title":"Tumor microenvironment-induced immunometabolic reprogramming of natural killer cells","volume":"9","author":"Chambers","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.semcancer.2019.05.018_bib0270","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.canlet.2016.05.012","article-title":"Role of the tumor microenvironment in regulating apoptosis and cancer progression","volume":"378","author":"Yaacoub","year":"2016","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.semcancer.2019.05.018_bib0275","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/cdd.2015.158","article-title":"Ferroptosis: process and function","volume":"23","author":"Xie","year":"2016","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0280","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12974-018-1235-0","article-title":"Necroptosis: a regulated inflammatory mode of cell death","volume":"15","author":"Dhuriya","year":"2018","journal-title":"J. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0285","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41418-018-0212-6","article-title":"Pyroptosis versus necroptosis: similarities, differences, and crosstalk","volume":"26","author":"Frank","year":"2019","journal-title":"Cell Death Differ."},{"issue":"8","key":"10.1016\/j.semcancer.2019.05.018_bib0290","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.spinee.2010.05.017","article-title":"Osteosarcoma of the spine: experience in 26 patients treated at the Massachusetts General Hospital","volume":"10","author":"Schoenfeld","year":"2010","journal-title":"Spine J."},{"issue":"6","key":"10.1016\/j.semcancer.2019.05.018_bib0295","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1179\/1743132814Y.0000000369","article-title":"En bloc resection of primary tumors of the thoracic spine: indications, planning, morbidity","volume":"36","author":"Boriani","year":"2014","journal-title":"Neurol. Res."},{"issue":"2","key":"10.1016\/j.semcancer.2019.05.018_bib0300","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00586-009-1137-z","article-title":"Morbidity of en bloc resections in the spine","volume":"19","author":"Boriani","year":"2010","journal-title":"Eur. Spine J."},{"issue":"2","key":"10.1016\/j.semcancer.2019.05.018_bib0305","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijrobp.2004.05.051","article-title":"Radiotherapy for local control of osteosarcoma","volume":"61","author":"DeLaney","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0310","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/01241398-199401000-00023","article-title":"Familial occurrence of telangiectatic osteosarcoma: cousin cases","volume":"14","author":"Nishida","year":"1994","journal-title":"J. Pediatr. Orthop."},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0315","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ocl.2008.10.004","article-title":"Primary malignant tumors of the spine","volume":"40","author":"Sundaresan","year":"2009","journal-title":"Orthop. Clin. North Am."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0320","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/978-1-4419-0284-9_29","article-title":"The role of Fas\/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases","volume":"152","author":"Gordon","year":"2009","journal-title":"Cancer Treat. Res."},{"issue":"2","key":"10.1016\/j.semcancer.2019.05.018_bib0325","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4161\/cbt.11.2.13966","article-title":"Gene expression profiles of human osteosarcoma cell sublines with different pulmonary metastatic potentials","volume":"11","author":"Chen","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0330","first-page":"7543","article-title":"BMP-2 inhibits lung metastasis of osteosarcoma: an early investigation using an orthotopic model","volume":"11","author":"Xiong","year":"2018","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0335","series-title":"Immune Environment and Osteosarcoma, Osteosarcoma - Biology, Behavior and Mechanisms","author":"Heymann","year":"2017"},{"issue":"3","key":"10.1016\/j.semcancer.2019.05.018_bib0340","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijrobp.2008.08.058","article-title":"Phase II study of high-dose photon\/proton radiotherapy in the management of spine sarcomas","volume":"74","author":"DeLaney","year":"2009","journal-title":"Int. J. Radiat. Oncol. Boil. Phys."},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0345","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/107327480501200104","article-title":"Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas","volume":"12","author":"DeLaney","year":"2005","journal-title":"Cancer Control"},{"key":"10.1016\/j.semcancer.2019.05.018_bib0350","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00586-015-4202-9","article-title":"Carbon-ion radiotherapy of spinal osteosarcoma with long-term follow","volume":"25","author":"Zhang","year":"2016","journal-title":"Eur. Spine J."},{"issue":"4","key":"10.1016\/j.semcancer.2019.05.018_bib0355","first-page":"252","article-title":"The blockade of immune checkpoints in cancer immunotherapy, Nature reviews","volume":"12","author":"Pardoll","year":"2012","journal-title":"Cancer"},{"issue":"6024","key":"10.1016\/j.semcancer.2019.05.018_bib0360","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.semcancer.2019.05.018_bib0365","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1172\/JCI80004","article-title":"From mice to humans: developments in cancer immunoediting","volume":"125","author":"Teng","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.semcancer.2019.05.018_bib0370","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1172\/JCI69219","article-title":"Radiation and immunotherapy: a synergistic combination","volume":"123","author":"Kalbasi","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.semcancer.2019.05.018_bib0375","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.semcancer.2019.05.018_bib0380","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00005-017-0491-5","article-title":"Immunotherapy as an option for Cancer treatment","volume":"66","author":"Rusch","year":"2018","journal-title":"Arch. Immunol. Ther. Exp. (Warsz.)"},{"issue":"3","key":"10.1016\/j.semcancer.2019.05.018_bib0385","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2217\/pme-2016-0108","article-title":"The swinging pendulum of cancer immunotherapy personalization","volume":"14","author":"Abraham","year":"2017","journal-title":"Per. Med."},{"issue":"11","key":"10.1016\/j.semcancer.2019.05.018_bib0390","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1080\/21645515.2017.1364322","article-title":"Cancer vaccines: enhanced immunogenic modulation through therapeutic combinations","volume":"13","author":"Gatti-Mays","year":"2017","journal-title":"Hum. Vacc. Immunother."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0395","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ctrv.2017.01.008","article-title":"The expanding role of immunotherapy","volume":"54","author":"Martin-Liberal","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"11","key":"10.1016\/j.semcancer.2019.05.018_bib0400","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"issue":"7109","key":"10.1016\/j.semcancer.2019.05.018_bib0405","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.semcancer.2019.05.018_bib0410","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","article-title":"PD-1 and PD-L1 antibodies in cancer: current status and future directions","volume":"66","author":"Balar","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"5256","key":"10.1016\/j.semcancer.2019.05.018_bib0415","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"7725","key":"10.1016\/j.semcancer.2019.05.018_bib0420","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/d41586-018-06751-0","article-title":"Cancer immunologists scoop medicine Nobel prize","volume":"562","author":"Ledford","year":"2018","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.semcancer.2019.05.018_bib0425","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.7150\/jca.25011","article-title":"Prognostic value of programmed cell death 1 Ligand-1 (PD-L1) or PD-1 expression in patients with osteosarcoma: a meta-analysis","volume":"9","author":"Huang","year":"2018","journal-title":"J. Cancer"},{"issue":"17","key":"10.1016\/j.semcancer.2019.05.018_bib0430","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1002\/cncr.30726","article-title":"T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas","volume":"123","author":"Pollack","year":"2017","journal-title":"Cancer"},{"issue":"7528","key":"10.1016\/j.semcancer.2019.05.018_bib0435","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"6332","key":"10.1016\/j.semcancer.2019.05.018_bib0440","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"issue":"35","key":"10.1016\/j.semcancer.2019.05.018_bib0445","doi-asserted-by":"crossref","first-page":"59570","DOI":"10.18632\/oncotarget.19168","article-title":"Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"issue":"25","key":"10.1016\/j.semcancer.2019.05.018_bib0450","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011004","article-title":"Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: a systematic review and meta-analysis","volume":"97","author":"Zheng","year":"2018","journal-title":"Medicine"},{"issue":"9","key":"10.1016\/j.semcancer.2019.05.018_bib0455","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/bjc.2015.124","article-title":"Anti-programmed cell death protein-1\/ligand-1 therapy in different cancers","volume":"112","author":"Homet Moreno","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2019.05.018_bib0460","article-title":"Role of the HDAC6\/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines","author":"Keremu","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"67","key":"10.1016\/j.semcancer.2019.05.018_bib0465","doi-asserted-by":"crossref","first-page":"111836","DOI":"10.18632\/oncotarget.22912","article-title":"Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8\/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1","volume":"8","author":"Palmerini","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.semcancer.2019.05.018_bib0470","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.990800","article-title":"CD8(+)\/FOXP3(+)-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study","volume":"4","author":"Fritzsching","year":"2015","journal-title":"Oncoimmunology"},{"issue":"SEP","key":"10.1016\/j.semcancer.2019.05.018_bib0475","first-page":"1","article-title":"T-cell-based immunotherapy for osteosarcoma: challenges and opportunities","volume":"7","author":"Wang","year":"2016","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.semcancer.2019.05.018_bib0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.27227","article-title":"Immunotherapy for osteosarcoma: Where do we go from here?","volume":"65","author":"Wedekind","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.semcancer.2019.05.018_bib0485","doi-asserted-by":"crossref","unstructured":"J. David, Zahavi, M. Louis, Weiner. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy. Int J Mol Sci. 2019 Jan; 20(1): 158.","DOI":"10.3390\/ijms20010158"},{"issue":"Pt 2","key":"10.1016\/j.semcancer.2019.05.018_bib0490","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semcancer.2017.10.001","article-title":"Emerging targets in cancer immunotherapy","volume":"52","author":"Burugu","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0495","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2017.01.001","article-title":"Second- and third-generation drugs for immuno-oncology treatment-The more the better?","volume":"74","author":"Dempke","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2019.05.018_bib0500","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/2326-6066.CIR-14-0039","article-title":"Tim-3: an emerging target in the cancer immunotherapy landscape","volume":"2","author":"Anderson","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.semcancer.2019.05.018_bib0505","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18030645","article-title":"TIM-3 as a target for Cancer immunotherapy and mechanisms of action","volume":"18","author":"Du","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.semcancer.2019.05.018_bib0510","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/2211-5463.12079","article-title":"Abnormal expression of Tim-3 antigen on peripheral blood T cells is associated with progressive disease in osteosarcoma patients","volume":"6","author":"Liu","year":"2016","journal-title":"FEBS Open Bio"},{"issue":"7","key":"10.1016\/j.semcancer.2019.05.018_bib0515","article-title":"Tim-3 as a diagnostic and prognostic biomarker of osteosarcoma","volume":"39","author":"Ge","year":"2017","journal-title":"J. Immunother. Emphasis Tumor Immunol."},{"issue":"2","key":"10.1016\/j.semcancer.2019.05.018_bib0520","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3892\/ol.2013.1410","article-title":"TIM-3 expression in human osteosarcoma: correlation with the expression of epithelial-mesenchymal transition-specific biomarkers","volume":"6","author":"Shang","year":"2013","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0525","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/14756366.2018.1471688","article-title":"A highly potent and selective inhibitor Roxyl-WL targeting IDO1 promotes immune response against melanoma","volume":"33","author":"Xu","year":"2018","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"2A","key":"10.1016\/j.semcancer.2019.05.018_bib0530","first-page":"931","article-title":"Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma","volume":"22","author":"Liebau","year":"2002","journal-title":"Anticancer Res."},{"issue":"8","key":"10.1016\/j.semcancer.2019.05.018_bib0535","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s10585-009-9290-7","article-title":"Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma","volume":"26","author":"Urakawa","year":"2009","journal-title":"Clin Exp Metastas"},{"issue":"12","key":"10.1016\/j.semcancer.2019.05.018_bib0540","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26642","article-title":"Severe cytokine release syndrome in a patient receiving PD-1-directed therapy","volume":"64","author":"Rotz","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.semcancer.2019.05.018_bib0545","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.semcancer.2019.05.018_bib0550","article-title":"Cardiotoxicity of Cancer therapies","author":"Mondal","year":"2018","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0555","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3389\/fphar.2018.01058","article-title":"Anticancer therapy-induced atrial fibrillation: electrophysiology and related mechanisms","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0560","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of Cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev."},{"issue":"9","key":"10.1016\/j.semcancer.2019.05.018_bib0565","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2019.05.018_bib0570","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw205","article-title":"Financial hardships experienced by Cancer survivors: a systematic review","volume":"109","author":"Altice","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0575","doi-asserted-by":"crossref","DOI":"10.1186\/s12904-018-0338-9","article-title":"The degree of social difficulties experienced by cancer patients and their spouses","volume":"17","author":"Takeuchi","year":"2018","journal-title":"BMC Palliat. Care"},{"issue":"13","key":"10.1016\/j.semcancer.2019.05.018_bib0580","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0585","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2217\/imt.14.98","article-title":"Adoptive cell therapy for sarcoma","volume":"7","author":"Mata","year":"2015","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.semcancer.2019.05.018_bib0590","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jocn.2010.11.034","article-title":"A phase I\/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma","volume":"18","author":"Chang","year":"2011","journal-title":"J. Clin. Neurosci."},{"issue":"288","key":"10.1016\/j.semcancer.2019.05.018_bib0595","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa7014","article-title":"Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma","volume":"7","author":"Noonan","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"26","key":"10.1016\/j.semcancer.2019.05.018_bib0600","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-Cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.semcancer.2019.05.018_bib0605","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-10-0712","article-title":"Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses","volume":"16","author":"Peng","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"25","key":"10.1016\/j.semcancer.2019.05.018_bib0610","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0615","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fimmu.2016.00353","article-title":"T-cell-Based immunotherapy for osteosarcoma: challenges and opportunities","volume":"7","author":"Wang","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0620","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2019.05.018_bib0625","first-page":"204","article-title":"Vaccines for tumour prevention, Nature reviews","volume":"6","author":"Lollini","year":"2006","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.semcancer.2019.05.018_bib0630","doi-asserted-by":"crossref","first-page":"273","DOI":"10.21037\/atm.2016.07.14","article-title":"Future perspectives in cancer immunotherapy","volume":"4","author":"Tsiatas","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0635","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/627254","article-title":"The genetics of osteosarcoma","author":"Martin","year":"2012","journal-title":"Sarcoma"},{"key":"10.1016\/j.semcancer.2019.05.018_bib0640","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bone.2016.10.017","article-title":"Molecular genetics of osteosarcoma","volume":"102","author":"Rickel","year":"2017","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.semcancer.2019.05.018_bib0645","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.semcancer.2019.05.018_bib0650","first-page":"630","article-title":"Targeting the cancer epigenome for therapy, Nature reviews","volume":"17","author":"Jones","year":"2016","journal-title":"Genetics"},{"issue":"3-4","key":"10.1016\/j.semcancer.2019.05.018_bib0655","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1615\/CritRevOncog.2015013713","article-title":"Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies","volume":"20","author":"Morrow","year":"2015","journal-title":"Crit. Rev. Oncog."},{"issue":"7","key":"10.1016\/j.semcancer.2019.05.018_bib0660","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1101\/gad.1787609","article-title":"An operational definition of epigenetics","volume":"23","author":"Berger","year":"2009","journal-title":"Genes Dev."},{"issue":"Suppl. 3","key":"10.1016\/j.semcancer.2019.05.018_bib0665","doi-asserted-by":"crossref","first-page":"S652","DOI":"10.21037\/tcr.2017.05.32","article-title":"Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy","volume":"6","author":"Lu","year":"2017","journal-title":"Transl. Cancer Res."},{"issue":"12","key":"10.1016\/j.semcancer.2019.05.018_bib0670","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122540","article-title":"The roles of microRNAs in regulating the expression of PD-1\/PD-L1 immune checkpoint","volume":"18","author":"Wang","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.semcancer.2019.05.018_bib0675","first-page":"1297","article-title":"MicroRNA-520b suppresses proliferation, migration, and invasion of spinal osteosarcoma cells via downregulation of Frizzled-8","volume":"25","author":"Wang","year":"2017","journal-title":"Oncol. Res. Featur. Preclin. Clin. Cancer Ther."},{"issue":"6","key":"10.1016\/j.semcancer.2019.05.018_bib0680","first-page":"989","article-title":"MicroRNA-373 promotes growth and cellular invasion in osteosarcoma cells by activation of the PI3K\/AKT\u2010Rac1\u2010JNK pathway: the potential role in spinal osteosarcoma","volume":"25","author":"Liu","year":"2017","journal-title":"Oncol. Res. Featur. Preclin. Clin. Cancer Ther."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0685","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3727\/096504017X15144741233346","article-title":"MicroRNA-103 promotes proliferation and inhibits apoptosis in spinal osteosarcoma cells by targeting p57","volume":"26","author":"Wang","year":"2018","journal-title":"Oncol. Res."},{"issue":"6121","key":"10.1016\/j.semcancer.2019.05.018_bib0690","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2019.05.018_bib0695","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00471","article-title":"RNA-programmed genome editing in human cells","volume":"2","author":"Jinek","year":"2013","journal-title":"eLife"},{"issue":"6121","key":"10.1016\/j.semcancer.2019.05.018_bib0700","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"issue":"33","key":"10.1016\/j.semcancer.2019.05.018_bib0705","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1038\/s41388-018-0292-2","article-title":"Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma","volume":"37","author":"Maurizi","year":"2018","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.semcancer.2019.05.018_bib0710","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1159\/000489072","article-title":"CRISPR-Cas9-Mediated silencing of CD44 in human highly metastatic osteosarcoma cells","volume":"46","author":"Liu","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0715","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.biomaterials.2017.09.015","article-title":"Tumor cell-targeted delivery of CRISPR\/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma","volume":"147","author":"Liang","year":"2017","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.semcancer.2019.05.018_bib0720","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.molcel.2016.10.038","article-title":"Mammalian RAD52 functions in break-induced replication repair of collapsed DNA replication forks","volume":"64","author":"Sotiriou","year":"2016","journal-title":"Mol. Cell"},{"issue":"19","key":"10.1016\/j.semcancer.2019.05.018_bib0725","doi-asserted-by":"crossref","first-page":"9379","DOI":"10.1093\/nar\/gkv993","article-title":"Nuclear domain\u2019 knock-in\u2019 screen for the evaluation and identification of small molecule enhancers of CRISPR-based genome editing","volume":"43","author":"Pinder","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.semcancer.2019.05.018_bib0730","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"issue":"18","key":"10.1016\/j.semcancer.2019.05.018_bib0735","doi-asserted-by":"crossref","first-page":"30276","DOI":"10.18632\/oncotarget.16326","article-title":"Targeting programmed cell death ligand 1 by CRISPR\/Cas9 in osteosarcoma cells","volume":"8","author":"Liao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2019.05.018_bib0740","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00586-006-0188-7","article-title":"Primary bone tumours of the spine: a 42-year survey from the Leeds Regional Bone Tumour Registry","author":"Kelley","year":"2007","journal-title":"Eur. Spine J."},{"key":"10.1016\/j.semcancer.2019.05.018_bib0745","series-title":"GeneReviews\u00ae","author":"Amemiya","year":"2018"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X18301561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X18301561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:38:50Z","timestamp":1760917130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X18301561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":149,"alternative-id":["S1044579X18301561"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2019.05.018","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapeutic strategies for spinal osteosarcomas","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2019.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}